ABCG2 Upregulation Involving AKT/NF-κB Signaling Contributes to Intestinal Barrier Dysfunction in Inflammatory Bowel Disease
Authors:
- 29 May 2026
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (10) , 1-13
Abstract
Background Previous investigations demonstrated significant upregulation of ATP-binding cassette subfamily G member 2 (ABCG2) in renal, hepatic, colonic, and intestinal tissues within a 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced murine model of Crohn’s disease (CD). Nevertheless, the regulatory mechanisms governing ABCG2 expression within inflammatory microenvironments and its consequent impact on intestinal barrier integrity remain incompletely elucidated. Aims This study aimed to elucidate the signaling pathway responsible for ABCG2 upregulation under inflammatory conditions and to investigate the functional role of ABCG2 in intestinal barrier integrity both in vitro and in vivo. Methods Intestinal epithelial barrier integrity was evaluated by measuring transepithelial electrical resistance (TEER), paracellular permeability to fluorescein isothiocyanate (FITC)-dextran, and immunofluorescence/immunoblot analysis of tight junction proteins. Abcg2−/− mice were utilized to evaluate the contribution of ABCG2 to intestinal barrier homeostasis. Results ABCG2 expression was observed to be significantly elevated in lipopolysaccharide (LPS)-stimulated intestinal epithelial cells. This induction coincided with enhanced phosphorylation of AKT and P65. Pharmacological inhibition of AKT (LY294002) or NF-κB (BAY117082) attenuated the LPS-mediated upregulation of ABCG2. Functional assessments revealed that pharmacological inhibition of ABCG2 (using Ko143) or its genetic ablation enhanced intestinal barrier integrity. This was evidenced by increased TEER, reduced permeability to FITC-dextran, and restored expression of key tight junction proteins (ZO-1, occludin, and claudin-1) following LPS challenge. Specifically, Abcg2 knockout improved colon length, preserved mucosal architectural integrity, and diminished inflammatory cell infiltration in both dextran sulfate sodium (DSS)-UC and TNBS-induced CD models. Conclusions ABCG2 reprents a promising therapeutic target for inflammatory bowel disease (IBD), particularly in patient populations exhibiting dysregulated transporter activity or genetic variants influencing drug response.Keywords
Funding Information
- Natural Scientific Fund of Chongqing Science and Technology Bureau (CSTB2023NSCQ-MSX0309)
This publication has 41 references indexed in Scilit:
- Transport mechanisms of pesticide mixtures impairing intestinal barrier function in micePesticide Biochemistry and Physiology, 2025
- ABCG2 plays a central role in the dysregulation of 25-hydrovitamin D in Crohn's diseaseThe Journal of Nutritional Biochemistry, 2023
- Differential expression of ABCB1, ABCG2, and KLF4 as putative indicators for paclitaxel resistance in human epithelial type 2 cellsMolecular Biology Reports, 2021
- Repression of PPARγ reduces the ABCG2-mediated efflux activity of M2 macrophagesThe International Journal of Biochemistry & Cell Biology, 2021
- Zinc enhances intestinal epithelial barrier function through the PI3K/AKT/mTOR signaling pathway in Caco-2 cellsThe Journal of Nutritional Biochemistry, 2017
- Inflamed pouch mucosa possesses altered tight junctions indicating recurrence of inflammatory bowel diseaseInternational Journal of Colorectal Disease, 2009
- The biological and clinical role of drug transporters at the intestinal barrierCancer Treatment Reviews, 2009
- PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like CellsCell Stem Cell, 2009
- Efflux transporters in ulcerative colitisInflammatory Bowel Diseases, 2007
- Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defenseToxicology and Applied Pharmacology, 2005